2 February 2026, London: 21shares, a leading global provider of crypto ETPs, is pleased to announce the appointment of Stephen Coltman as Head of Macro, effective at the beginning of February. This senior hire further strengthens 21shares’ investment team as the company expands its active portfolio management capabilities. Stephen will work closely with Eliézer Ndinga, Adrian Fritz and the Capital Markets team, focusing on portfolio and risk management for the firm’s new active products. In this newly created role, Stephen will also provide broad financial market commentary and support client interactions, utilising his wealth of experience to further enhance 21shares’ investment insights and client service. He will be based in the firm’s London office. With 25 years’ experience as a trader, macro strategist and hedge fund portfolio manager,...

Suominen Corporation February 2, 2026 at 10:00 a.m. (EET) Charles Héaulmé has reported to have made transactions with Suominen Corporation’s shares. The transactions are presented below as a summary, and in detail as per the disclosure requirement. Acquisitions on January 29, 2026:Total amount 10 000 shares Volume weighted average price EUR 1.6700Suominen Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Charles HéaulméPosition: Chief Executive OfficerIssuer: Suominen OyjLEI: 743700Z1BNFYR9PRDF52Notification type: INITIAL NOTIFICATIONReference number: 140780/4/4 ____________________________________________Transaction date: 2026-01-29Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009010862Nature of transaction: ACQUISITION Transaction...

REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand. “These agreements with Sandoz further advance Alvotech’s strategy of securing commercial pathways for its biosimilars portfolio across global markets ahead of regulatory approval,” said Róbert Wessman, Chairman. “These partnerships reflect the strength of our integrated development and manufacturing platform and our ability to work with experienced regional partners to expand patient access while maintaining capital discipline.” In Canada, the agreement...

REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand. “These agreements with Sandoz further advance Alvotech’s strategy of securing commercial pathways for its biosimilars portfolio across global markets ahead of regulatory approval,” said Róbert Wessman, Chairman. “These partnerships reflect the strength of our integrated development and manufacturing platform and our ability to work with experienced regional partners to expand patient access while maintaining capital discipline.” In Canada, the agreement covers one biosimilar...

To Nasdaq Copenhagen A/S                        2 February 2026                                        Announcement no. 10/2026 Jyske Realkredit’s auctions for 1 April 2026 refinancing Jyske Realkredit plans to carry out the auctions Tuesday 3th of February through Thursday 5th of February 2026 for loans in cover pool E. The refinancing amount and bonds to be offered are specified in the table below:Date Open Close Alloc. Name ISIN Amount (DKK million) LCRTuesday 3 February 09:30 10:00 10:05 1% JRK 1/4-2029 SDO DK0009395956 1425 1B  10:00 10:30 10:35 1% JRK 1/4-2031 SDO DK0009404378 1650 1B  12:30 13:00 13:05 1% JRK 1/4-2027 SDO (IT) DK0009417438 1000 –               Wednesday 4 February 09:30 10:00 10:05 1% JRK 1/4-2029 SDO DK0009395956 1425 1B  10:00 10:30 10:35 1% JRK 1/4-2031 SDO DK0009404378 1650 1B  12:30 13:00 13:05 1%...

Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumors MP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026 Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D.ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...

The year 2025 was the first full year in the operating history of EfTEN United Property Fund in which the Fund did not make new larger investments, and the financial results reflected the full performance of the existing portfolio. During the year, the Fund generated its highest net profit to date, increasing 2.2 times compared to 2024. In 2025, EfTEN United Property Fund earned a net profit of 3.57 million euros (2024: 1.62 million euros), representing approximately 14% of the Fund’s invested capital and around 17% of its market capitalisation. The Fund’s revenues increased from 1.82 million euros to 3.78 million euros year-on-year, and in 2025 the Fund made distributions to investors in an amount exceeding 9% of its market capitalisation.  The Fund’s financial performance was supported primarily by the improved profitability of the Uus-Järveküla residential...

CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) DIJON, France – February 2, 2026 (7:15 a.m. CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company that develops products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology. CROSSJECT is in the advanced stages of developing and registering ZEPIZURE®, an injectable for the treatment of epileptic seizures, and announces the initiation of coverage of its stock by Portzamparc (BNP Paribas Group). Coverage of CROSSJECT shares has been initiated with a study entitled “The needles will soon be nothing more than a bad memory” which includes a “Strong Buy” recommendation with a target price of €4.50. CROSSJECT shares are now covered by:– Alpha Value– Invest Securities–...